Karyopharm Therapeutics | KPTI - Interest Expense On Debt


Karyopharm Therapeutics reported $12.55M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AbbVie USD 688M 58M Sep/2026
Abbott USD 297M 2M Sep/2026
Amgen USD 653M 94.99B Sep/2026
AstraZeneca USD 371M 31M Sep/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
Eli Lilly USD 316M 201.3M Sep/2026
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
GlaxoSmithKline GBP 219M 98M Sep/2026
Incyte USD 605K 23K Sep/2026
J&J USD 43M 25M Mar/2026
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
MacroGenics USD 4.4M 493K Jun/2026
Merck USD 525M 46M Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Novartis USD 468M 6M Sep/2026
Novartis USD 281M 8M Sep/2025
Pfizer USD 662M 5M Sep/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Takeda JPY 63.38B 466M Sep/2026
Tectonic Therapeutic USD 237.03M 9.54M Jun/2026
TG Therapeutics USD 16.57M 8.91M Jun/2026
Ultragenyx Pharmaceutical USD 20M 2M Sep/2026
Xencor USD 4.11M 3.24M Sep/2026